References
- Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total?. Bioanalysis 2010; 2:1125 - 40; http://dx.doi.org/10.4155/bio.10.64; PMID: 21083212
- Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, et al. Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J 2011; 13:99 - 110; http://dx.doi.org/10.1208/s12248-011-9251-3; PMID: 21240643
- Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995; 34:10474 - 82; http://dx.doi.org/10.1021/bi00033a020; PMID: 7654701
- Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011; 25:13 - 25; http://dx.doi.org/10.2165/11539590-000000000-00000; PMID: 21090841
- Friedberg JW, Vose JM, Kahl BS, Brunvand MW, Goy A, Kasamon YL, et al. A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20_ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. ASH Annual Meeting. New Orleans, LA: Blood, 2009:3742.
- Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, et al, ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:2652 - 61; http://dx.doi.org/10.1002/art.23732; PMID: 18759293
- Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47:1119 - 28; http://dx.doi.org/10.1177/0091270007305297; PMID: 17766699
- Morschhauser F, Marlton P, Vitolo U, Lindén O, Seymour JF, Crump M, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010; 21:1870 - 6; http://dx.doi.org/10.1093/annonc/mdq027; PMID: 20157180
- Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, et al. Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease. Br J Haematol 2003; 123:850 - 7; http://dx.doi.org/10.1046/j.1365-2141.2003.04683.x; PMID: 14632776
- Manshouri T, Do KA, Wang X, Giles FJ, O’Brien SM, Saffer H, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101:2507 - 13; http://dx.doi.org/10.1182/blood-2002-06-1639; PMID: 12446458
- Keating MJ, O’Brien S, Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol 2002; 29:Suppl 2 70 - 4; http://dx.doi.org/10.1053/sonc.2002.30142; PMID: 11842391
- Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000; 27:Suppl 12 17 - 24; PMID: 11225995
- Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45:792 - 801; http://dx.doi.org/10.1177/0091270005277075; PMID: 15951469